Jump to Main Content
- Bapurao Surnar; Nagesh Kolishetti; Uttara Basu; Anis Ahmad; Erik Goka; Brian Marples; David Kolb; Marc E. Lippman; Shanta Dhar
- Biochemistry 2018 v.57 no.46 pp. 6500-6513
- DNA; DNA damage; adverse effects; antineoplastic activity; aspirin; cisplatin; drug therapy; in vitro studies; models; nausea; nephrotoxicity; neurotoxicity; patients; urinary bladder neoplasms
- ... Cisplatin is a major chemotherapeutic that continues to have a significant impact in the treatment of more than 50% of all cancers. Since its Food and Drug Administration approval in 1978 for the treatment of advanced ovarian and bladder cancer, this chemotherapeutic has made significant strides and its application has been extended to a large variety of other cancers. However, the vast majority o ...
- Giovanni Sitia; Roberto Aiolfi; Pietro Di Lucia; Marta Mainetti; Amleto Fiocchi; Francesca Mingozzi; Antonio Esposito; Zaverio M. Ruggeri; Francis V. Chisari; Matteo Iannacone; Luca G. Guidotti
- Proceedings of the National Academy of Sciences of the United States of America 2012 v.109 no.32 pp. E2165
- T-lymphocytes; adverse effects; animal models; antineoplastic activity; aspirin; chronic exposure; chronic hepatitis B; hepatoma; hepatotoxicity; liver; liver cirrhosis; pathogenesis; risk factors; therapeutics; transgenic animals
- ... Chronic infection with hepatitis B virus (HBV) is a major risk factor for the development of hepatocellular carcinoma (HCC). The pathogenesis of HBV-associated HCC involves both viral and host factors. The latter include a functionally inefficient CD8 ⁺ T-cell response that fails to clear the infection from the liver but sustains a chronic necroinflammatory process that contributes to the developm ...
- PubMed Central: